Frequency and expression of mutational resistance to the 4-quinolone antibacterials. 1986

J T Smith

The frequency with which Escherichia coli mutated to resist a series of ten 4-quinolone antibacterials was studied. It was found that the mutation frequency could not be predicted from the potency of the drugs against sensitive bacteria. The mutation rates were lowest with ofloxacin, norfloxacin and ciprofloxacin. No mutants were observed with ofloxacin while less mutants were observed with norfloxacin than with ciprofloxacin, despite the latter possessing greatest activity against susceptible bacteria. The mutation frequencies observed with nalidixic acid, cinoxacin, pipemidic acid, flumequine, rosoxacin, oxolinic acid, and enoxacin were much higher than those observed with the three 4-quinolones mentioned earlier. When the sensitivities of the mutants to 4-quinolones were investigated, it was again found that the potency of each 4-quinolone against sensitive bacteria did not correlate with the levels of resistance of mutants to that drug. However, when the relative activities of the 4-quinolones against the mutants were investigated, it was found that no mutant isolated resisted a concentration exceeding the peak serum levels of ciprofloxacin, norfloxacin or ofloxacin. Although some mutants exhibited more resistance than the maximum attainable serum levels of the other 4-quinolones, the sensitivity of all the mutants fell well within the urine levels of pipemidic acid, flumequine, rosoxacin, oxolinic acid, enoxacin, norfloxacin, ofloxacin, and ciprofloxacin.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009268 Nalidixic Acid A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE. Nalidixin,Nalidixate Sodium,Nalidixate Sodium Anhydrous,Nevigramon,Sodium Nalidixic Acid, Anhydrous,Sodium Nalidixic Acid, Monohydrate,Acid, Nalidixic,Anhydrous, Nalidixate Sodium,Sodium Anhydrous, Nalidixate,Sodium, Nalidixate
D009287 Naphthyridines A group of two-ring heterocyclic compounds consisting of a NAPHTHALENES double ring in which two carbon atoms, one per each ring, are replaced with nitrogens.
D009643 Norfloxacin A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. AM-0715,AM-715,MK-0366,MK-366,MK0366,MK366,Noroxin,AM 0715,AM 715,AM0715,MK 0366,MK 366
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D010093 Oxolinic Acid Synthetic antimicrobial related to NALIDIXIC ACID and used in URINARY TRACT INFECTIONS. Gramurin,Sodium Oxolinate,Acid, Oxolinic,Oxolinate, Sodium
D010876 Pipemidic Acid Antimicrobial against Gram negative and some Gram positive bacteria. It is protein bound and concentrated in bile and urine and used for gastrointestinal, biliary, and urinary infections. Piperamic Acid,Deblaston,Galusan,Nuril,Palin,Pipram,Urisan,Uropipemid,Acid, Pipemidic,Acid, Piperamic
D011804 Quinolines
D011807 Quinolizines
D002937 Cinoxacin Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS. Azolinic Acid,Cinobac,Clinoxacin,Compound 64716,Acid, Azolinic

Related Publications

J T Smith
January 1992, Drug safety,
J T Smith
January 1992, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques,
J T Smith
February 2007, Nihon rinsho. Japanese journal of clinical medicine,
J T Smith
November 2013, Antimicrobial agents and chemotherapy,
J T Smith
November 1990, Journal of pharmaceutical sciences,
J T Smith
January 1992, Drug safety,
J T Smith
December 1990, The Journal of antimicrobial chemotherapy,
J T Smith
March 1998, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!